Cogent Biosciences Files 8-K on Financials
Ticker: COGT · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1622229
| Field | Detail |
|---|---|
| Company | Cogent Biosciences, INC. (COGT) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, results-of-operations, filing
TL;DR
Cogent Biosciences dropped an 8-K on Nov 3rd detailing their financial condition. Check it for the latest numbers.
AI Summary
Cogent Biosciences, Inc. filed an 8-K on November 3, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts.
Why It Matters
This filing provides investors with an update on Cogent Biosciences' financial performance and condition, which is crucial for evaluating the company's operational health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing (8-K) and does not appear to contain any new material events or significant negative news.
Key Numbers
- 001-38443 — SEC File Number (Identifies the company's filing history with the SEC.)
- 46-5308248 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Cogent Biosciences, Inc. (company) — Registrant
- November 3, 2025 (date) — Date of Report
- 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451 (location) — Principal executive offices
- Unum Therapeutics Inc. (company) — Former company name
FAQ
What specific financial statements are included in this 8-K filing?
The filing explicitly states that 'Financial Statements and Exhibits' are included as Item Information, but the specific details of these statements are not provided in the excerpt.
When was Cogent Biosciences, Inc. previously known by another name?
The company was formerly known as Unum Therapeutics Inc., with a name change date of April 2, 2018, and also previously as Unum Therapeutics, Inc. with a name change date of October 14, 2014.
What is the Standard Industrial Classification (SIC) code for Cogent Biosciences, Inc.?
The SIC code listed for Cogent Biosciences, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Where are Cogent Biosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 275 Wyman Street, 3rd Floor, Waltham, Massachusetts 02451.
What is the fiscal year end for Cogent Biosciences, Inc.?
The fiscal year end for Cogent Biosciences, Inc. is December 31 (1231).
Filing Stats: 519 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-03 09:13:20
Key Financial Figures
- $0.001 — nge on which registered Common stock, $0.001 Par Value COGT The Nasdaq Global Se
Filing Documents
- cogt-20251103.htm (8-K) — 59KB
- cogt-ex99_1.htm (EX-99.1) — 94KB
- img214414700_0.jpg (GRAPHIC) — 231KB
- 0001193125-25-261797.txt ( ) — 591KB
- cogt-20251103.xsd (EX-101.SCH) — 28KB
- cogt-20251103_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 3, 2025, Cogent Biosciences, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety. The information in this Item 2.02 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Cogent Biosciences, Inc. on November 3, 2025, furnished herewith. 104 The cover page from the Company's Current Report on Form 8-K formatted in Inline XBRL.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 3, 2025 COGENT BIOSCIENCES, INC. By: /s/ John Green John Green Chief Financial Officer